Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises

American Journal of the Medical Sciences

Volumn 325, Issue 3, 2003, Pages 107-109

  Prasad, Rajinder ^a   Hasan, Syed ^a,c   Castro, Oswaldo ^a   Perlin, Elliott ^a   Kim, Kyungsook ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c HOWARD UNIVERSITY   (United States)

Author keywords

Mortality in sickle cell disease; Sickle cell disease; Vaso occlusive crises

Indexed keywords

HYDROXYUREA;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; SEX DIFFERENCE; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRANSFUSION; TREATMENT OUTCOME;

EID: 0037344078     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200303000-00001     Document Type: Article

References (12)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
2. Platt OS, Thorington BD, Brambila DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-6.
3. Charache S, Terrin ML, Moore R, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
4. Rodgers GP, Walker BC, Podgor MD. Mortality in sickle cell disease [letter]. N Eng J Med 1994;331:1022-3.
5. Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am 1996;10:1289-303.
6. Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001;125:1436-41.
7. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
8. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
9. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle cell erythocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701-10.
10. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 1997;89:1078-88.
11. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
12. Davies SC. Bone marrow transplant for sickle cell disease - the dilemma. Blood Rev 1993;7:4-9.